PMID- 24996416
OWN - NLM
STAT- MEDLINE
DCOM- 20150515
LR  - 20211021
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 16
IP  - 4
DP  - 2014 Jul 4
TI  - Discriminant validity, responsiveness and reliability of the arthritis-specific 
      Work Productivity Survey assessing workplace and household productivity in 
      patients with psoriatic arthritis.
PG  - R140
LID - 10.1186/ar4602 [doi]
AB  - INTRODUCTION: The novel arthritis-specific Work Productivity Survey (WPS) was 
      developed to estimate patient productivity limitations associated with arthritis 
      within and outside the home, which is an unmet need in psoriatic arthritis (PsA). 
      The WPS has been validated in rheumatoid arthritis. This report assesses the 
      discriminant validity, responsiveness and reliability of the WPS in adult-onset 
      PsA. METHODS: Psychometric properties were assessed using data from the RAPID-PsA 
      trial (NCT01087788) investigating certolizumab pegol (CZP) efficacy and safety in 
      PsA. WPS was completed at baseline and every 4 weeks until Week 24. Validity was 
      evaluated at baseline via known-groups defined using first and third quartiles of 
      patients' Disease Activity Score 28 based on C-reactive protein (DAS28(CRP)), 
      Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form-36 (SF-36) 
      items and PsA Quality of Life (PsAQoL) scores. Responsiveness and reliability 
      were assessed by comparing WPS mean changes at Week 12 in American College of 
      Rheumatology 20% improvement criteria (ACR20) or HAQ-DI Minimal Clinically 
      Important Difference (MCID) 0.3 responders versus non-responders, as well as 
      using standardized response means (SRM). All comparisons were conducted on the 
      observed cases in the Randomized Set, regardless of the randomization group, 
      using a non-parametric bootstrap-t method. RESULTS: Compared with patients with a 
      better health state, patients with a worse health state had on average 2 to 6 
      times more household work days lost, more days with reduced household 
      productivity, more days missed of family/social/leisure activities, more days 
      with outside help hired and a significantly higher interference of arthritis per 
      month. Among employed patients, those with a worse health state had 2 to 4 times 
      more workplace days lost, more days with patient workplace productivity reduced, 
      and a significantly higher interference of arthritis on patient workplace 
      productivity versus patients with a better health state. WPS was also responsive 
      to clinical changes, with responders having significantly larger improvements at 
      Week 12 in WPS scores versus non-responders. The effect sizes for changes in 
      productivity in ACR20 or HAQ-DI MCID responders were moderate (0.5 < SRM < 0.8) 
      or small. CONCLUSIONS: These analyses demonstrate the validity, responsiveness 
      and reliability of the WPS, as an instrument for the measurement of patient 
      productivity within and outside the home in an adult-onset PsA population.
FAU - Osterhaus, Jane T
AU  - Osterhaus JT
FAU - Purcaru, Oana
AU  - Purcaru O
LA  - eng
SI  - ClinicalTrials.gov/NCT01087788
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20140704
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Immunosuppressive Agents)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - UMD07X179E (Certolizumab Pegol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Arthritis, Psoriatic/drug therapy/*psychology
MH  - Certolizumab Pegol
MH  - Data Collection/*instrumentation
MH  - Double-Blind Method
MH  - *Efficiency/drug effects
MH  - Female
MH  - Humans
MH  - Immunoglobulin Fab Fragments/therapeutic use
MH  - Immunosuppressive Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/therapeutic use
MH  - Psychometrics/*methods
MH  - Reproducibility of Results
MH  - Workplace
MH  - Young Adult
PMC - PMC4226958
EDAT- 2014/07/06 06:00
MHDA- 2015/05/16 06:00
PMCR- 2014/07/04
CRDT- 2014/07/06 06:00
PHST- 2013/09/16 00:00 [received]
PHST- 2014/06/17 00:00 [accepted]
PHST- 2014/07/06 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2015/05/16 06:00 [medline]
PHST- 2014/07/04 00:00 [pmc-release]
AID - ar4602 [pii]
AID - 10.1186/ar4602 [doi]
PST - epublish
SO  - Arthritis Res Ther. 2014 Jul 4;16(4):R140. doi: 10.1186/ar4602.